Search
for
Sort by
Research 91–120 of 376
- Optimal Management of Plaque Psoriasis in Adolescents: Current Perspectives
- Hormone receptor positive, HER2 negative metastatic breast cancer: Impact of CDK4/6 inhibitors on the current treatment paradigm
- Reliability and Validity of a Photographic Method for Measuring Facial Hair Density in Men
- Improvement of Psoriasis, Psoriatic Arthritis, and Alopecia Universalis during Treatment with Tofacitinib: A Case Report
- The association of male pattern baldness and risk of cancer and high-grade disease among men presenting for prostate biopsy
- Dutasteride: A Review of its Use in the Management of Prostate Disorders
- Platelet Immune Interactions, Lifespan, and Senescence
- Evaluation of short-term hair follicle storage conditions for maintenance of RNA integrity
- γδ17 T cell-stromal networks modulate matrix composition and vascularity in foreign body response
- Long-term Efficacy and Safety of Ritlecitinib in Adults and Adolescents with Alopecia Areata: 3-year Results from the ALLEGRO-LT Phase 3, Open-label Study
- Hair Oils May Worsen Seborrheic Dermatitis in Black Patients
- Industry update: the latest developments in the field of therapeutic delivery, July 2018
- Alopecia in three women of southeast asian descent with chronic renal failure: Possible association with erythropoietin use
- The Specific Dermatoses of Pregnancy
- Hair Loss and Androgen’s Role in the Era of COVID-19
- Australasian Society for Dermatology Research Meeting, May 2006
- A Cost-per-Responder Analysis of Ritlecitinib vs Baricitinib in Severe Alopecia Areata
- Aged differentiated cells reverse into native stemness-like state by niche cytokines to sustain lifelong homeostasis and tissue repair
- How Long to Treat to Achieve Desired Treatment Outcomes with Baricitinib 4 mg in Severe Alopecia Areata: Evidence-based Approach
- Corrective and Restorative Dermatology in Cancer Survivors: An Urgent Unmet Need!
- Long-Term Efficacy and Safety of Ritlecitinib in Adults and Adolescents with Alopecia Areata: 3-Year Results from the ALLEGRO Phase 2b/3 and ALLEGRO-LT Phase 3 Clinical Studies
- All Subcomponents of the Cutaneous Lupus Erythematosus Disease Area and Severity Index–Activity (CLASI-A) are Relevant to Identify and Detect Changes in Skin Activity
- The Intersection of Sleep and Hair Loss: A Systematic Review
- Most Baricitinib Responders Achieved Full Scalp Hair Regrowth: Findings from Adult and Paediatric BRAVE-AA Trials
- Efficacy, Safety, and Tolerability of Upadacitinib in Adults and Adolescents With Severe Alopecia Areata: Results From the Randomized, Placebo-Controlled, Double-Blind Phase 3 Program (UP-AA)
- Baricitinib Provides Significant Hair Regrowth In Adolescents With Severe Alopecia Areata: 52-Week Efficacy and Safety Results From A Phase 3 Randomized, Controlled Trial
- Baricitinib Provides Holistic Improvement in Scalp, Eyebrow and Eyelash Regrowth in Adolescents With Severe Alopecia Areata
- A Systematic Literature Review of Alopecia Areata in Children and Adolescents: Psychosocial Impact
- Baricitinib Provides Higher Efficacy in Adolescents Relative to Adults With Alopecia Areata Despite More Severe Disease at Baseline: 36-Week Outcomes From BRAVE-AA Trials
- Farmácia São Lázaro - Porto e nos Serviços Farmacêuticos do Hospital Privado de Vila Real (Grupo Trofa Saúde) - Vila Real